Internal dose assessment of $^{210}$Po using biokinetic modeling and urinary excretion measurement

Wei Bo Li · Udo Gerstmann · Augusto Giussani · Uwe Oeh · Herwig G. Paretzke

Received: 8 May 2007 / Accepted: 5 September 2007 / Published online: 25 September 2007 © Springer-Verlag 2007

Abstract The mysterious death of Mr. Alexander Litvinenko who was most possibly poisoned by Polonium-210 ($^{210}$Po) in November 2006 in London attracted the attention of the public to the kinetics, dosimetry and the risk of this high radiotoxic isotope in the human body. In the present paper, the urinary excretion of seven persons who were possibly exposed to traces of $^{210}$Po was monitored. The values measured in the GSF Radioanalytical Laboratory are in the range of natural background concentration. To assess the effective dose received by those persons, the time-dependence of the organ equivalent dose and the effective dose after acute ingestion and inhalation of $^{210}$Po were calculated using the biokinetic model for polonium (Po) recommended by the International Commission on Radiological Protection (ICRP) and the one recently published by Leggett and Eckerman (L&E). The daily urinary excretion to effective dose conversion factors for ingestion and inhalation were evaluated based on the ICRP and L&E models for members of the public. The ingestion (inhalation) effective dose per unit intake integrated over one day is $1.7 \times 10^{-8} \ (1.4 \times 10^{-7}) \ \text{Sv Bq}^{-1}, \ 2.0 \times 10^{-7} \ (9.6 \times 10^{-7}) \ \text{Sv Bq}^{-1}$ over 10 days, $5.2 \times 10^{-7} \ (2.0 \times 10^{-6}) \ \text{Sv Bq}^{-1}$ over 30 days and $1.0 \times 10^{-6} \ (3.0 \times 10^{-6}) \ \text{Sv Bq}^{-1}$ over 100 days. The daily urinary excretions after acute ingestion (inhalation) of 1 Bq of $^{210}$Po are $1.1 \times 10^{-3} \ (1.0 \times 10^{-4})$ on day 1, $2.0 \times 10^{-3} \ (1.9 \times 10^{-4})$ on day 10, $1.3 \times 10^{-3}$ (1.7 $\times 10^{-4}$) on day 30 and $3.6 \times 10^{-4} \ (8.3 \times 10^{-5}) \ \text{Bq d}^{-1}$ on day 100, respectively. The resulting committed effective doses range from $2.1 \times 10^{-3}$ to $1.7 \times 10^{-2} \ \text{mSv}$ by an assumption of ingestion and from $5.5 \times 10^{-2}$ to $4.5 \times 10^{-1} \ \text{mSv}$ by inhalation. For the case of Mr. Litvinenko, the mean organ absorbed dose as a function of time was calculated using both the above stated models. The red bone marrow, the kidneys and the liver were considered as the critical organs. Assuming a value of lethal absorbed dose of 5 Gy to the bone marrow, 6 Gy to the kidneys and 8 Gy to the liver, the amount of $^{210}$Po which Mr. Litvinenko might have ingested is therefore estimated to range from 27 to 1,408 MBq, i.e 0.2–8.5 $\mu$g, depending on the modality of intake and on different assumptions about blood absorption.

Introduction

Polonium-210 ($^{210}$Po) is a natural radionuclide which decays to $^{206}$Pb, emitting alpha particles with energy of 5.3044 (100%) and 4.5166 MeV (0.00122%) [1]. The half-life of $^{210}$Po is 138.376 days [1], which corresponds to a specific activity of $1.66 \times 10^{14} \ \text{Bq g}^{-1}$. High amounts of pure $^{210}$Po activity can be produced by three ways: the activation of $^{209}$Bi (natural abundance 100%) with thermal neutrons (cross section $\sigma = 0.034$ barn), the separation from $^{222}$Rn daughter nuclides emanated from $^{226}$Ra, and the separation from Pb–Bi alloy coolants of some fast neutron reactors.

$^{210}$Po is a decay daughter of $^{210}$Pb in $^{238}$U decay chain of the uranium series; it occurs in the uranium ores and exists ubiquitously in the environment. According to the United Nations Scientific Committee on the Effects of Atomic
Radiation (UNSCEAR) [2], the concentration of $^{210}\text{Po}$ in air is reported to be from 10 to 80 $\mu\text{Bq m}^{-3}$ with a reference value of 50 $\mu\text{Bq m}^{-3}$; the annual intake of the public ranges from 18 Bq in South America to 220 Bq in Asia with a reference value of 58 Bq. Through inhalation and diet $^{210}\text{Po}$ is accumulated in the human body, its concentration in human tissues is 200 mBq kg$^{-1}$ in lungs, 600 mBq kg$^{-1}$ in liver, 600 mBq kg$^{-1}$ in kidneys, 100 mBq kg$^{-1}$ in muscle and other tissues, and 2,400 mBq kg$^{-1}$ in bone. However, these body contents are reference values, they vary between individuals. The presence of $^{210}\text{Po}$ in tobacco greatly increases the intake of this radionuclide by smokers. Recently, Desideri et al. [3] reported that in Italy smokers who smoke 20 cigarettes per day inhale, on average, 79.5 mBq of $^{210}\text{Po}$ daily; those smokers concomitantly inhale the same amount of radioactivity from $^{210}\text{Pb}$. The measured $^{210}\text{Po}$ concentration in lung parenchyma of smokers is about three times that of non-smokers [4]. Hill reported a higher content of $^{210}\text{Po}$ in kidneys, liver, lungs, and gonads for smokers compared to non-smokers [5].

With regard to daily excretion, Glöbel et al. [6] reported in 1966 the measurements in one German subject to be in the range of 40.7–351.5 mBq in feces and 2.2–37 mBq in urine. Naumann et al. [7] reported daily urinary excretion ranging from 2.8 (detection limit of 2 mBq l$^{-1}$ with urinary excretion of 1.4 l d$^{-1}$) to 9.9 mBq d$^{-1}$ in Berlin area. Dalheimer et al. [8] recently reported a daily urinary excretion median value of 3.5 mBq d$^{-1}$ for non-smokers and 6.6 mBq d$^{-1}$ for smokers. In Brazil, the reported values of $^{210}\text{Po}$ excretion in urine were 5.2 mBq l$^{-1}$ for non-smokers and 9.8 mBq l$^{-1}$ for smokers [9, 10]. In Saudi Arabia, the measured values range from 1.5 to 10 mBq l$^{-1}$ for non-smokers and 3.3 to 15.9 mBq l$^{-1}$ for smokers [11].

According to the model recommended by the International Commission on Radiological Protection (ICRP), about 10–50% of ingested $^{210}\text{Po}$ is absorbed by the intestine and flows into the bloodstream and mostly deposits in the liver, kidneys, spleen, red bone marrow and other tissues [12]. To distinguish between ingestion of the organic and inorganic forms of polonium, ICRP recommended an $f_1$ value of 0.1 for workers and 0.5 for members of the public [12]. For intake by inhalation, ICRP recommended an $f_1$ value of 0.1 for workers and members of the public inhaling the material of Type F (fast absorption into blood) and M (moderate absorption into blood) [13, 14], an $f_1$ value of 0.01 was used for members of the public inhaling the material of Type S (slow absorption into blood) [14]. The effective dose coefficients of $^{210}\text{Po}$ for adult members of the public recommended by ICRP are $1.2 \times 10^{-6} \text{ Sv Bq}^{-1}$ for ingestion calculated with an $f_1$ value of 0.5, and $3.3 \times 10^{-6} \text{ Sv Bq}^{-1}$ for inhalation assuming a material of Type M with an $f_1$ value of 0.1 [14].

As reported in the media, Mr. Alexander Litvinenko died 23 days (the 23rd of November 2006 was included) after he was possibly poisoned by $^{210}\text{Po}$. In this context, the organ absorbed doses in the days following, say from days 1 to 30, after acute intake of $^{210}\text{Po}$ are important for intake lethal dose estimation. The equivalent dose and effective dose coefficients are needed for the effective dose and the risk assessments of other probably contaminated members of the public.

In the present work, the daily urinary and fecal excretions, the time-dependence of the equivalent dose and the effective dose from 1 to 1,000 days after acute ingestion and inhalation of 1 Bq of $^{210}\text{Po}$ were calculated using the biokinetic model for polonium recommended by ICRP [12] and the model recently developed by Leggett and Eckerman (L&E) [15]. These modeled excretions and dose coefficients can be used for the estimate of intake and the risk assessment, provided that the $^{210}\text{Po}$ urinary or other excreta data are available from the people who were potentially contaminated in this $^{210}\text{Po}$ accident. The GSF Radioanalytical Laboratory measured urine samples of seven German subjects who were suspected to have been exposed to traces of $^{210}\text{Po}$ in the aftermath of the poisoning of Mr. Litvinenko. Those measured results and the calculated conversion factors of the daily urinary excretion to effective dose are applied to assess the effective dose for those persons. In order to estimate the possible intake of $^{210}\text{Po}$ and organ dose for Mr. Litvinenko, the mean organ absorbed dose was calculated applying the two above-mentioned models. The results obtained using ICRP and L&E models are compared and critically discussed.

**Materials and methods**

Experimental measurement of urinary excretion of $^{210}\text{Po}$

Seven persons (5 male and 2 female) aged from 23 to 48 years from Germany provided their 24-h urine samples in December 2006. Among those persons only one was a smoker. Information on the suspected day of exposure to $^{210}\text{Po}$ was also acquired. Samples were measured between 6 and 12 days after the possible exposure. The complete 24-h urine samples were transferred into appropriate glass beakers. The sampling containers were washed twice with 20 ml 9 M HCl. The washing solutions were added to the samples. About 160 mBq $^{208}\text{Po}$ yield tracer and 1 g ascorbic acid per liter urine were added. Polonium was deposited onto copper discs (20 h, 20°C). The urine was discarded and the discs were rinsed with water and isopropanol. The polonium isotopes were determined by alpha spectrometry with Canberra PIPS detectors in
vacuum chambers. The spectra were evaluated with Eurosys Interwinner Software. The analytical procedure was last validated by participating in the IAEA proficiency test IAEA-CU-2007-09 on the determination of $^{210}$Po in water.

**Biokinetic model of $^{210}$Po**

The ICRP and L&E systemic biokinetic models of polonium [12, 15], coupled with the gastrointestinal tract model of ICRP Publication 30 [16] and the respiratory tract model of ICRP Publication 66 [17], were used to calculate the retentions of $^{210}$Po in organs or tissues after incorporation. In the ICRP model, a fraction of 30, 10, 5, 10, and 45% of polonium entering into the systemic circulation is deposited in the liver, kidneys, spleen, red marrow and the rest of the body, respectively. It is retained in those organs with a half-life of 50 days. A ratio of 1:2 between the urinary and fecal excretions is assumed for systemic polonium [12]. Recently, an improved, physiologically realistic systemic biokinetic model for polonium in humans was constructed by Leggett and Eckerman based on the data identified to most likely represent the typical behavior of polonium in laboratory animals and human subjects [15]. In contrast to the current ICRP model, the new proposed model enables one to predict the excretion of polonium in human hair and sweat. In addition, a compartment representing the bone surface was added, to which the excretion of polonium in human hair and sweat. In contrast to the current ICRP model, the new proposed model enables one to predict the excretion of polonium in human hair and sweat.

**Results and discussion**

Firstly, the measured $^{210}$Po urinary excretion is presented. Secondly, the time-dependent organ equivalent dose, effective dose, organ absorbed dose and daily excretion in urine and in feces, in hair and sweat after acute ingestion and inhalation of $^{210}$Po are shown. The average values of body content and daily excretion of $^{210}$Po for the normal unexposed public are estimated. Finally, the effective doses for the possibly contaminated seven subjects are predicted. The amount of $^{210}$Po Mr. Litvinenko probably ingested are estimated and discussed based on different assumptions.

**Measured $^{210}$Po urinary excretion**

Figure 1 shows one alpha spectrum of the samples. The $^{208}$Po tracer contained some $^{209}$Po impurities. However, this did not interfere with the determination of $^{210}$Po. In Table 1, the $^{210}$Po activities (±1 combined standard uncertainty) of seven 24-h-urine samples are shown. Daily urinary excretion ranged from 3.3 to 26.4 mBq d$^{-1}$, with a mean value of 11.3 mBq d$^{-1}$. All these values are in the range of natural levels, and below the reported level of 30 mBq d$^{-1}$ set by the Health Protection Agency (HPA) [22].

$^{210}$Po organ equivalent dose and effective dose after acute intake

The equivalent and effective doses per unit intake for members of the public and for workers after acute ingestion and inhalation using both the ICRP and L&E models are
presented in Fig. 2. The time-dependent equivalent and effective doses incline to a constant value after 300 days of acute intake. The effective dose coefficient for inhalation is generally higher than for ingestion. The organ equivalent doses of public are higher than that of workers because the $f_i$ value of 0.5 recommended for the members of the public is higher than the value of 0.1 for workers.

By inhalation, the total deposition of inhaled aerosols in the whole respiratory tract for workers is 1.7 times higher than that of the public. However, for workers, about 74% of the total inhaled aerosols are assumed to be deposited in the extrathoracic (ET) region, which gives less contribution to the resulting dose coefficient, in comparison to the public, for which only 32% is assumed to be deposited in ET region. The deposition in the alveolar–interstitial (AI) region of the lungs for public is two times higher than that for the workers [17]. Therefore, the dose coefficient of the lungs is higher for the public. This higher equivalent dose in lungs makes a slightly higher effective dose for the public.

For most organs, e.g. kidneys, liver, red marrow and spleen, the organ equivalent dose calculated using the ICRP model is generally higher than that by the L&E model. By inhalation, the lung doses are the main contribution to the effective dose and they are almost identical between the two models. Anyway, the effective doses by the two models show a smaller discrepancy than the change in organ equivalent doses. For members of the public, the effective dose coefficients range from $1.7 \times 10^{-8}$ Sv Bq$^{-1}$ on the first day, $2.0 \times 10^{-7}$ Sv Bq$^{-1}$ on the 10th day, $5.2 \times 10^{-7}$ Sv Bq$^{-1}$ on the 30th day, to a constant value of $1.2 \times 10^{-6}$ Sv Bq$^{-1}$ in the later days for acute ingestion; and $1.4 \times 10^{-7}, 9.6 \times 10^{-7}, 2.0 \times 10^{-6}, 3.3 \times 10^{-6}$ Sv Bq$^{-1}$ for acute inhalation on the same mentioned days with the ICRP model, respectively.

$^{210}$Po mean organ absorbed dose after acute intake

In order to assess deterministic effects of exposure to $^{210}$Po, organ absorbed dose was also calculated. The time-dependence of the organ absorbed dose after acute intake of $^{210}$Po is shown in Fig. 3. Because $^{210}$Po is an alpha emitter (negligible contribution to dose from gamma ray), the organ absorbed doses are 20 times smaller than the corresponding values of the organ equivalent dose since a radiation weighting factor of 20 for alpha particles is applied in calculating the organ equivalent dose. The highest organ absorbed doses are in the kidneys after intake for ingestion, and in the lungs after inhalation. Doses to members of the public are generally higher than for workers; the L&E model gives lower estimates than the ICRP model. The dose absorbed by the red marrow per unit ingestion (inhalation), calculated using the ICRP model for members of the public, is $1.5 \times 10^{-3}$ (1.4 $\times 10^{-5}$) Gy MBq$^{-1}$ at 1 day after incorporation, $2.2 \times 10^{-2}$ (2.1 $\times 10^{-3}$) Gy MBq$^{-1}$ at 10 days, $5.7 \times 10^{-2}$ (6.0 $\times 10^{-3}$) Gy MBq$^{-1}$ at 30 days, and $1.1 \times 10^{-1}$ (1.5 $\times 10^{-2}$) Gy MBq$^{-1}$ at 100 days, respectively.

Table 1

| Subject number | Volume of 24-h-urine sample (l) | Measured daily excretion (mBq d$^{-1}$) | Ingestion $E$ (mSv) | Ingestion $E'$ (mSv) | Inhalation $E$ (mSv) | Inhalation $E'$ (mSv) | Estimated amount (mBq) |
|----------------|---------------------------------|----------------------------------------|----------------------|----------------------|---------------------|---------------------|----------------------|
| #1             | 0.92                            | 4.5 ± 1.2                              | 2.8 $E$ – 03         | 4.8 $E$ – 04         | 7.6 $E$ – 02        | 2.2 $E$ – 02        | 2.3                   |
| #2             | 3.35                            | 10.8 ± 2.8                             | 6.8 $E$ – 03         | 1.3 $E$ – 03         | 1.8 $E$ – 01        | 5.8 $E$ – 02        | 5.7                   |
| #3             | 2.74                            | 12.4 ± 1.5                             | 8.0 $E$ – 03         | 1.6 $E$ – 03         | 2.1 $E$ – 01        | 7.1 $E$ – 02        | 6.6                   |
| #4             | 1.50                            | 9.5 ± 1.5                              | 5.6 $E$ – 03         | 5.8 $E$ – 04         | 1.6 $E$ – 01        | 3.1 $E$ – 02        | 4.6                   |
| #5             | 2.25                            | 12.4 ± 3.4                             | 7.5 $E$ – 03         | 9.0 $E$ – 04         | 2.1 $E$ – 01        | 4.6 $E$ – 02        | 6.2                   |
| #6             | 2.01                            | 3.3 ± 1.0                              | 2.1 $E$ – 03         | 3.5 $E$ – 04         | 5.5 $E$ – 02        | 1.6 $E$ – 02        | 1.7                   |
| #7             | 3.42                            | 26.4 ± 3.2                             | 1.7 $E$ – 02         | 2.8 $E$ – 03         | 4.5 $E$ – 01        | 1.3 $E$ – 01        | 13.6                  |
| Mean           |                                 | 11.3                                   |                      |                      |                     |                     |                      |
| Median         |                                 | 10.8                                   |                      |                      |                     |                     |                      |

Fig. 1 Alpha spectrum of $^{208/209/210}$Po isolated from one 24-h-urine sample. $^{209}$Po is an impurity of the $^{208}$Po tracer.
\[ \text{ICRP Public Ingestion} \]

\[ \text{ICRP Worker Ingestion} \]

\[ \text{L&E Public Ingestion} \]

\[ \text{L&E Worker Ingestion} \]

Fig. 2 Time-dependence of organ equivalent dose and effective dose coefficient after acute ingestion and inhalation for members of the public and the workers by using the systemic models recommended by ICRP [12] and the model developed recently by Leggett and Eckerman (L&E) [15], combining the gastrointestinal tract and the human respiratory tract models [16, 17]. The line legend symbols, which are shown in the figure, are applicable for the others. The title of “ICRP Public/Workers Ingestion/Inhalation” represents the ICRP model for members of the public/the workers by ingestion/inhalation.

\[ \text{ICRP Public Inhalation} \]

\[ \text{ICRP Worker Inhalation} \]

\[ \text{L&E Public Inhalation} \]

\[ \text{L&E Worker Inhalation} \]

\[ 210\text{Po daily excretion in urine and in feces after acute intake} \]

The predicted daily excretions in urine and in feces, by using both models, are shown in Fig. 4. The lower intestinal absorption, assumed for the workers, results in a higher value in their fecal excretions. For both the public and the workers, the daily urinary and fecal excretions by ingestion are much higher than that by inhalation. By means of the L&E model, the excretion of \( 210\text{Po} \) in human hair and sweat could be used to estimate the intake and the level of \( 210\text{Po} \) in the human body, provided that the measured amount of \( 210\text{Po} \) in hair is available. However, it is not obvious to assess the intake and level of \( 210\text{Po} \) in the body from hair measurements because their results are highly dependent on modality of sample collection and because the model does not discriminate between excretion into sweat and hair. In the first few days after incorporation, the amount of \( 210\text{Po} \) excreted in urine is markedly higher than that in hair and sweat (of a factor up to 25 times). This factor is predicted to be smaller at later times, reaching about the value of 1 approximately 100 days after intake.

By using the ICRP model, the predicted daily urinary excretions of \( 210\text{Po} \) for members of the public are \( 1.1 \times 10^{-3} \text{ Bq d}^{-1} \) on the first day, \( 2.0 \times 10^{-3} \text{ Bq d}^{-1} \) on the 10th day, \( 1.3 \times 10^{-3} \text{ Bq d}^{-1} \) on the 30th day and \( 3.6 \times 10^{-4} \text{ Bq d}^{-1} \) on the 100th day after acute ingestion of 1 Bq of \( 210\text{Po} \); and \( 1.0 \times 10^{-4}, 1.9 \times 10^{-4}, 1.7 \times 10^{-4} \) and \( 8.3 \times 10^{-5} \text{ Bq d}^{-1} \) on same mentioned days after acute inhalation, respectively.

\[ 210\text{Po dose conversion factor of daily urinary excretion to effective dose} \]

To enable an easy calculation of the effective dose for the persons whose urinary excretion were measured, the daily urinary excretion to effective dose conversion factor were calculated based on the ICRP and L&E models. They are tabulated in Table 2. There are two kinds of conversion factors presented in Table 2, namely, E/U and E’/U, where E is the effective dose coefficient, as defined and recommended by ICRP; E’ is the effective dose by the time T after intakes. In the earlier days, the factor E/U is larger.
Time-dependence of mean organ absorbed dose after acute ingestion and inhalation for members of the public and the workers by using the systemic models recommended by ICRP [12] and the model developed recently by Leggett and Eckerman (L&E) [15], combining the gastrointestinal tract and the human respiratory tract models [16, 17]. The legend symbols, which are shown in the figure, are applicable for the others. The title of “ICRP Public/Workers Ingestion/Inhalation” represents the ICRP model for members of the public/the workers by ingestion/inhalation.

than E'/U, however, after 300 days from intake, those two factors reach the same value. For example, if one has inhaled 1 Bq of $^{210}$Po, according to the ICRP model for members of the public, the resulting effective dose E' is $1.4 \times 10^{-7}$ by T = 1 day, $2.0 \times 10^{-6}$ by T = 30 days and $3.3 \times 10^{-6}$ Sv Bq$^{-1}$ by T = 50 years. The effective dose E' released at the time of urine collection can be estimated. It represents approximately the lower limits of dose released by $^{210}$Po in the earlier days. Since measurements were generally conducted few days after sampling, the results of the activity measurements in urine needed to be corrected for radioactive decay in order to obtain the actual activity value at the day of urine collection.

$^{210}$Po body content and urinary and fecal excretion for normal unexposed people

According to the average concentration of $^{210}$Po in the foodstuffs and in the air reported by UNSCEAR [2], the normal unexposed person ingests 0.16 Bq and inhales 1 mBq of $^{210}$Po each day. Applying the ICRP model for members of the public, the content of $^{210}$Po in human body is predicted to be about 1.1 Bq. It is estimated that about 4 mBq in urine and 0.15 Bq in feces could be found daily. These results are in excellent agreement with the experimental values reported in the literature [6–11, 22, 23].

Internal dose assessment for the monitored subjects

Although the measured excreted activities were comparable to the natural levels, and below the threshold set by the HPA to identify individuals probably exposed to $^{210}$Po from the London incident [22], effective doses were nonetheless calculated under the pessimistic assumption that the measured activities were actually due to an acute intake on the day of suspected exposure to $^{210}$Po. In Table 1 the values of committed effective dose E (over 50 years) and E' (till the day of sample collection) are presented as estimated from the results of the measurements in urine. The intakes of inhalation and ingestion
Estimating ²¹⁰Po intake for Mr. Alexander Litvinenko

As reported in the media, Mr. Litvinenko was most possibly poisoned on 1 November 2006 and died 23 days later on 23 November at 21:21 o’clock. From the available information, it is possible to assume that polonium was administered orally, and that multiple organ failure, probably connected with bone marrow syndrome, was responsible for the death of Mr. Litvinenko.

As Harrison et al. [24] pointed out, animal studies showed that multiple organ damages were the cause of deaths within few weeks from intake of ²¹⁰Po. The results of the biokinetic modeling presented above indicated that kidneys, liver and red marrow could be the critical organs, being among the organs with the highest absorbed dose coefficients. According to the data presented by Harrison et al. [24], the lethal dose LD₅₀ may be estimated as about 3–4 Gy for the bone marrow syndrome, 6 Gy for acute kidneys damage and 8 Gy for acute liver damage. An LD₁₀₀ of 5 Gy for red marrow syndrome is also given. Those values were calculated for internal irradiation from ²¹⁰Po, taking into account relative biological effectiveness (RBE) of alpha particles and dose protraction. The absorbed dose of 5 Gy to red marrow, 6 Gy to kidneys and 8 Gy to liver were applied as a basis on the organ lethal dose in this work to estimate the possible intake of ²¹⁰Po by Mr. Litvinenko.

The organ absorbed dose coefficients were calculated for day 23 after ingestion (the day of 23 November was included as full day in the calculations) in the present work. The resulting dose coefficients are $4.6 \times 10^{-2} (1.8 \times 10^{-2})$ Gy MBq⁻¹ for red bone marrow, $2.2 \times 10^{-1} (1.3 \times 10^{-1})$ Gy MBq⁻¹ for kidneys, and $6.0 \times 10^{-1} (2.5 \times 10^{-1})$ Gy MBq⁻¹ for liver.

As a result, the effective dose $E'$ is much lower than the value of $E$. When using the systemic models recommended by ICRP [12] and the model developed recently by Leggett and Eckerman [15], coupled with the gastrointestinal tract and the human respiratory tract models [16, 17], the resulting effective doses range from 2.1 to 1.7 Gy by ingestion, and from 5.5 to 4.5 mSv by inhalation. Under the very restrictive and pessimistic assumptions used for these evaluations, the dose received would be considerably lower than the natural background radiation dose contributed from ²¹⁰Po.

**Fig. 4** Daily urinary and fecal excretions for members of the public and the workers after acute ingestion and inhalation of 1 Bq of ²¹⁰Po by using the systemic models recommended by ICRP [12] and the effective dose method.
Table 2 Daily urinary excretion to effective dose conversion factor (mSv per mBq d⁻¹) for adult members of the public

| Δt (day) | Ingestion | | | | | Inhalation | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | E/U | E'/U | | | | E/U | E'/U | | | | |
| 1 | 1.1E – 03 | 1.6E – 05 | | | | | | | | | |
| 3 | 5.4E – 04 | 2.8E – 05 | | | | | | | | | |
| 5 | 5.6E – 04 | 4.9E – 05 | | | | | | | | | |
| 7 | 5.9E – 04 | 7.0E – 05 | | | | | | | | | |
| 10 | 6.2E – 04 | 1.0E – 04 | | | | | | | | | |
| 12 | 6.6E – 04 | 1.4E – 04 | | | | | | | | | |
| 15 | 6.8E – 04 | 1.7E – 04 | | | | | | | | | |
| 17 | 7.1E – 04 | 1.9E – 04 | | | | | | | | | |
| 20 | 7.5E – 04 | 2.3E – 04 | | | | | | | | | |
| 21 | 7.6E – 04 | 2.5E – 04 | | | | | | | | | |
| 22 | 7.8E – 04 | 2.6E – 04 | | | | | | | | | |
| 23 | 7.9E – 04 | 2.8E – 04 | | | | | | | | | |
| 24 | 8.1E – 04 | 2.9E – 04 | | | | | | | | | |
| 25 | 8.2E – 04 | 3.1E – 04 | | | | | | | | | |
| 30 | 9.1E – 04 | 3.9E – 04 | | | | | | | | | |
| 40 | 1.1E – 03 | 5.8E – 04 | | | | | | | | | |
| 50 | 1.3E – 03 | 8.0E – 04 | | | | | | | | | |
| 60 | 1.6E – 03 | 1.1E – 03 | | | | | | | | | |
| 70 | 1.9E – 03 | 1.4E – 03 | | | | | | | | | |
| 80 | 2.3E – 03 | 1.8E – 03 | | | | | | | | | |
| 90 | 2.8E – 03 | 2.3E – 03 | | | | | | | | | |
| 100 | 3.4E – 03 | 2.9E – 03 | | | | | | | | | |
| 200 | 2.2E – 02 | 2.2E – 02 | | | | | | | | | |
| 300 | 1.5E – 01 | 1.5E – 01 | | | | | | | | | |
| 500 | 6.5E + 00 | 6.5E + 00 | | | | | | | | | |
| 700 | 2.6E + 02 | 2.6E + 02 | | | | | | | | | |
| 1,000 | 6.4E + 04 | 6.4E + 04 | | | | | | | | | |

E denotes the time elapsed from assumed exposure to sample collection. E' denotes the effective dose coefficient at 50 years after intake. U denotes the daily urinary excretion at the time of interest. L&E model denotes model developed by Leggett and Eckerman. For ingestion, f₁ value of 0.5 is assumed. For inhalation, the absorption material of Type M, f₁ value of 0.1 and an activity median aerodynamic diameter (AMAD) of 1 μm are assumed.

Gy MBq⁻¹ for kidneys, 1.1 × 10⁻¹ (8.5 × 10⁻²) Gy MBq⁻¹ for liver with ICRP (L&E) model, assuming an f₁ value of 0.5; and 9.2 × 10⁻³ (3.6 × 10⁻²) Gy MBq⁻¹ for red bone marrow, 4.4 × 10⁻² (2.6 × 10⁻²) Gy Bq⁻¹ for kidneys, 2.3 × 10⁻² (1.7 × 10⁻²) Gy MBq⁻¹ for liver assuming an f₁ value of 0.1.

The estimation of possible intake of ²¹⁰Po is summarized in Table 3. Both of the ICRP and L&E models were used. According to different f₁ values of 0.5 and 0.1, the estimated amounts of ²¹⁰Po range from 27 to 1,408 MBq, corresponding to 0.2 to 8.5 μg. Moreover, the organ absorbed doses, calculated after an incorporation of estimated amount of ²¹⁰Po assuming the red bone marrow as a critical organ with an absorbed dose of 5 Gy, are presented in Table 4. In their paper, Harrison et al. [24] concluded that 0.1–0.3 GBq or more absorbed to blood of an adult male is likely to be fatal within 1 month. This range would correspond to an intake of 200–600 MBq assuming 50% absorption to blood and to 1–3 GBq assuming 10% absorption to blood, respectively. These values are consistent with the estimates obtained in the present work.

Conclusions

In this work, the time-dependent organ equivalent dose, effective dose and daily excretion in urine and in feces after an acute intake of ²¹⁰Po are calculated by applying the models of polonium recommended by ICRP and the new model developed recently by Leggett and Eckerman. The
conversion factors from the daily urinary excretion to the effective dose were evaluated. Moreover, the 24-h-urine samples of seven persons who were possibly contaminated were measured in the GSF Radioanalytical Laboratory. Their measured excretions resulted within the natural level of the excretion rate of $^{210}$Po, and below the threshold limit value of 30 mBq d$^{-1}$ recommended by the HPA to identify individuals probably exposed to $^{210}$Po from the London incident. The effective dose was estimated for those seven persons using their measured urinary excretion and the calculated conversion factors. They were in the range of $2.1 \times 10^{-3}$ to $1.7 \times 10^{-2}$ mSv assuming an intake by ingestion, and $5.5 \times 10^{-2}$ to $4.5 \times 10^{-1}$ mSv by inhalation. They are much lower than the mean effective dose of 2.4 mSv to the population in the federal republic of Germany during the year 2005 [25]. From the fact that the measured results were within the natural level of the excretion rate of $^{210}$Po, it is concluded that no additional $^{210}$Po intake can be detected. Thus, no excess health effects related to the toxicity of $^{210}$Po are expected for those monitored subjects besides the background exposure to the natural level of $^{210}$Po.

Table 3 Possible incorporation of $^{210}$Po estimated for Mr. Alexander Litvinenko using the biokinetic models of ICRP [12] and L&E [15] with the assumption of different damaged organ and the lethal absorbed dose

| Biokinetic model | ICRP | L&E | ICRP | L&E | ICRP | L&E | ICRP | L&E | ICRP | L&E |
|------------------|------|-----|------|-----|------|-----|------|-----|------|-----|
| $f_1$ Value      | 0.1  | 0.1 | 0.5  | 0.5 | 0.1  | 0.1 | 0.5  | 0.5 | 0.1  | 0.1 |
| Estimated intake |      |     |      |     |      |     |      |     |      |     |
| (MBq)            | 546  | 1,408 | 109 | 281 | 136  | 230 | 27   | 46  | 351  | 473 |
| (μg)             | 3.3  | 8.5  | 0.7  | 1.7 | 0.8  | 1.4 | 0.2  | 0.3 | 2.1  | 2.9 |

a Critical organ
b Lethal absorbed dose

Table 4 Estimated incorporation and organ absorbed doses based on different assumptions of lethal red bone marrow dose of 5 Gy with $f_1$ values of 50 and 10% for blood absorption

| Assumption | #1$^a$ | #2$^b$ | #3$^c$ | #4$^d$ | #5$^e$ | #6$^f$ | #7$^g$ | #8$^h$ |
|------------------|------|-----|------|-----|------|-----|------|-----|
| Intake           |      |     |      |     |      |     |      |     |
| (μg)             | 0.7  | 1.7 | 2.4  | 2.4 | 3.3  | 8.5 | 12.0 | 12.0 |
| (MBq)            | 109  | 281 | 400  | 400 | 546  | 1,408| 2,000| 2,000|
| Bone surface (Gy)|      |     |      |     |      |     |      |     |
| Stomach (Gy)     |      |     |      |     |      |     |      |     |
| Small intestine (Gy)|      |     |      |     |      |     |      |     |
| Colon (Gy)       |      |     |      |     |      |     |      |     |
| Kidneys (Gy)     |      |     |      |     |      |     |      |     |
| Liver (Gy)       |      |     |      |     |      |     |      |     |
| Red bone marrow (Gy)|      |     |      |     |      |     |      |     |
| Spleen (Gy)      |      |     |      |     |      |     |      |     |

a Lethal red bone marrow dose 5 Gy using ICRP model with $f_1 = 0.5$
b Lethal red bone marrow dose 5 Gy using L&E model with $f_1 = 0.5$
c 0.4 GBq ingestion using ICRP model with $f_1 = 0.5$
d 0.4 GBq ingestion using L&E model with $f_1 = 0.5$
e Lethal red bone marrow dose 5 Gy using ICRP model with $f_1 = 0.1$
f Lethal red bone marrow dose 5 Gy using L&E model with $f_1 = 0.1$
g 2 GBq ingestion using ICRP model with $f_1 = 0.1$
h 2 GBq ingestion using L&E model with $f_1 = 0.1$
Acknowledgments  We thank the Research Centre Jülich for providing us rapidly with $^{208}$Po tracer. We thank Ms. V. Tschöpp and Mr. R. Lindner for performing the radiochemical analysis. Special thanks are due to Dr. Linda Walsh for linguistically reading the manuscript.

References

1. Firestone RB (1996) Table of isotopes, 8th CD-ROM edn. Wiley, New York
2. United Nations (2000) Sources and effects of ionizing radiation: 2000 report to the general assembly, with scientific annexes, vol 1. Annex B. United Nations Scientific Committee on the Effects of Atomic Radiation, United Nations, New York
3. Desideri D, Meli MA, Feduzzi L, Roselli C (2007) $^{210}$Po and $^{210}$Pb inhalation by cigarette smoking in Italy. Health Phys 92:58–63
4. Rajewsky B, Stahlhoven W (1966) Polonium-210 activity in the lungs of cigarette smokers. Nature 209:1312–1313
5. Hill CR (1965) Polonium-210 in man. Nature 208:423–428
6. Glo¨bel B, Muth H, Oberhausen E (1966) Aufnahme und Ausscheidung der natürlichen Radionuklide $^{210}$Pb und $^{210}$Po durch den Menschen. Strahlentherapie 131:218–226
7. Naumann M, Hänisch K, Hartmann M (1998) Levels of natural radionuclides in human excreta in the Berlin area. Radiat Prot Dosim 79:197–200
8. Dalheimer A, König K, Noßke D, Schäfer I (2007) Der Hamburger Poloniumfall aus sicht der Inkorporations-Überwachung. In: Bayer A, Faleschini H, Krüger S, Strobl Chr (Bandherausgeber) Vorkehrungen und Massnahmen bei Radiologischen Ereignissen. 5. Seminar des Arbeitskreises Notfallschutz. Augsburg, 25. bis 27. April 2007. Bericht Nr. FS-07–142-AKN. Publikationsreihe Fortschritte im Strahlenschutz. Fachverband für Strahlenschutz e.V., TÜV Media GmbH, Köln, pp 82–88
9. Lipsztein JL, Melo DR, Sousa W, Dias da Cunha KM, Azeredo AMG, Julião L, Santos M (2003) Norm workers: a challenge for internal dosimetry programmes. Radiat Prot Dosim 105:317–320
10. Santos PL, Gouvea RC, Dutra IR (1994) Concentrations of $^{210}$Pb and $^{210}$Po in hair and urine of workers, of the uranium mine at Pocos de Caldas (Brazil) Sci Total Environ 148:61–65
11. Al-Arifi MN, Alkarfy KM, Al-Suwayeh SA, Aleissa KA, Shabana EI, Al-Dhuwaili AA, Al-Hassan MI (2006) Levels of $^{210}$Po in blood, urine and hair of some Saudi smokers. J Radioanal Nucl Chem 269:115–118
12. ICRP (1993) Age-dependent doses to members of the public from intake of radionuclides: Part 2 ingestion dose coefficients. Annals of ICRP 23 (3/4). Pergamon, Oxford
13. ICRP (1994) Dose coefficients for intakes of radionuclides by workers. Annals of ICRP 24 (4). Pergamon, Oxford
14. ICRP (1996) Age-dependent doses to members of the public from intake of radionuclides: Part 5 compilation of ingestion and inhalation dose coefficients. Annals of ICRP 26 (1). Pergamon, Oxford
15. Leggett RW, Eckerman KF (2001) A systemic biokinetic model for polonium. Sci Total Environ 275:109–125
16. ICRP (1979) Limits on intakes of radionuclides for workers. Part I. Annals of the ICRP 2 (3–4). Pergamon, Oxford
17. ICRP (1994) Human respiratory tract model for radiological protection. Annals of the ICRP 24 (1–3). Pergamon, Oxford
18. Loevinger R, Berman M (1976) A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No. 1, Revised. Society of Nuclear Medicine, New York
19. ICRP (1995) Age-dependent doses to members of the public from intake of radionuclides: Part 4 inhalation dose coefficients. Annals of the ICRP 25 (3–4). Pergamon, Oxford
20. Cristy M, Eckerman KF (1993) SEECAL: program to calculate age-dependent specific effective energies. ORNL/TM-12351, Oak Ridge National Laboratory, Oak Ridge
21. ICRP (1991) 1990 Recommendations of the International Commission on Radiological Protection. Annals of the ICRP 21 (1–3). Pergamon, Oxford
22. HPA (2007) Assessment of doses from measurements of Polonium-210 in urine, Health Protection Agency. http://www.hpa.org.uk/polonium/Dose_Assessment.pdf. Cited 15 March 2007
23. Spencer H, Holtzman RB, Kramer L, Ilcewicz FH (1977) Metabolic balances of $^{210}$Pb and $^{210}$Po at natural levels. Radiat Res 69:166–184
24. Harrison J, Leggett R, Lloyd D, Phipps A, Scott B (2007) Polonium-210 as a poison. J Radiol Prot 27:17–40
25. BMU (2006) Umweltradioaktivität und Strahlenbelastung Jahresbericht 2005. Bundesministerium für Umwelt, Naturschutz und Reaktorsicherheit, Bonn